SecBot SecBot
8-K ·Filed Aug 6, 2026

TFX

TELEFLEX INC
MIXED
Impact 6/10
Horizonweeks Processed3mo ago SEC0000096943-26-000091
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

The earnings beat and raised EPS guidance are positive, but the revenue guidance cut signals a slower growth trajectory for the core business. Traders should watch for execution on the Biotronik integration and the pace of share repurchases. The FDA approval of EZPLAZ provides a new long-term catalyst, but near-term focus will be on whether the company can stabilize organic growth trends.

DirectionMixed
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$138.89
T+0 close · Aug 6, 2026 · via day close
Latest settled
+0.63%
T+60 · $139.77
Vs SPY
+2.30%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 6 $138.89entry
  2. T+1 · 3mo ago −2.82%α −3.43% · $134.98
  3. T+5 · 3mo ago −1.09%α −2.31% · $137.37
  4. T+20 · 3mo ago +0.77%α +0.17% · $139.96
  5. T+60 · 18d ago +0.63%α +2.30% · $139.77
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Teleflex reported Q2 2026 adjusted EPS of $1.76, a 37.4% beat vs the $1.28 consensus, driven by strong Vascular and Surgical growth and aggressive capital return. However, the company reduced its full-year pro forma adjusted constant currency revenue growth guidance to 3.5%-4.5% (from 4.5%-5.5%) due to slower-than-expected integration of the acquired Biotronik Vascular Intervention business, creating a mixed picture of earnings upside against a top-line growth deceleration.

Key Financial Metrics

EPS
$1.76
est $1.28 · +37.5%
Revenue
$570.3M
est $559.6M · +1.9% · +28.9% YoY
Rating
beat
Guidance
$2.26B-$2.28B
Gross Margin
58.2%

Key Facts

  • Q2 2026 adjusted EPS of $1.76 beat consensus of $1.28 by 37.4%
  • Q2 2026 revenue of $570.3M beat consensus of $559.6M by 1.9%
  • Full-year pro forma adjusted constant currency revenue growth guidance reduced to 3.5%-4.5% from 4.5%-5.5%
  • Full-year adjusted EPS guidance raised to $6.90-$7.20 from $6.25-$6.55
  • Completed $1.5B OEM divestiture; deployed $250M for share repurchases in Q2 and announced a $250M accelerated share repurchase
  • Paid off $700M Term Loan A-2 and refinanced credit facilities
  • Received FDA BLA approval for EZPLAZ Freeze Dried Plasma
  • Integration of Biotronik Vascular Intervention business taking longer than expected, impacting revenue outlook

Financial Impact

Q2 adjusted EPS beat consensus by $0.48 (37.4%); full-year adjusted EPS guidance raised by $0.65 at midpoint; full-year revenue growth guidance reduced by ~100bps at midpoint

revenueepsguidancedebtdilution

Risk Factors

  • Slower-than-expected Biotronik integration could lead to further revenue guidance reductions
  • Activist investor campaign may create strategic uncertainty or force suboptimal capital allocation
  • Execution risk on achieving ~$50M in annualized restructuring savings by mid-2028
  • Potential IEEPA tariff refunds are excluded from guidance, creating uncertainty in cash flow

Market Snapshot

Exchange
NYSE
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
41% bullish (17 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0000096943-26-000091
Exhibit: exhibit992to8-6x2026req2.htm0000096943-26-000091
Document: tfx-20260806.htm0000096943-26-000091
Document: 0000096943-26-000091-index-headers.html0000096943-26-000091
Document: 0000096943-26-000091-index.html0000096943-26-000091
Document: 0000096943-26-000091.txt0000096943-26-000091
8-K Data (Synthetic)0000096943-26-000091

Track record

11 reports on TFX

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $154.69 Now $155.10 +0.27% settles Nov 23
  2. Nov 5, 202611d ago 8-K Bullish 6/10 Entry $152.15 to $153.15 Now $155.10 +1.94% ▲ +0.66% −2.63% vs SPY
  3. Aug 6, 202614w ago 8-K Mixed 6/10 Viewing Entry $138.89 to $137.37 Now $155.10 +11.67% ▼ −1.09% −2.31% vs SPY
  4. Jul 2, 202619w ago Court Ruling Bullish 6/10 Entry $133.99 to $134.04 Now $155.10 +15.75% ▲ +0.04% −0.89% vs SPY
  5. Jun 22, 202621w ago Institutional Cluster Mixed 4/10 Entry $121.67 to $129.86 Now $155.10 +27.48% ▲ +6.73% +8.80% vs SPY
  6. Jun 15, 202622w ago 8-K Neutral 4/10 Entry $127.87 to $124.26 Now $155.10 +21.30% ▼ −2.82% −0.59% vs SPY
  7. Jun 9, 202622w ago 8-K Neutral 2/10 Entry $132.15 to $127.87 Now $155.10 +17.37% ▼ −3.24% −6.67% vs SPY
  8. Jun 1, 202624w ago 8-K Neutral 4/10 Entry $127.31 to $129.84 Now $155.10 +21.82% ▲ +1.98% +4.73% vs SPY
  9. May 27, 202624w ago 8-K Neutral 4/10 Entry $128.90 to $131.04 Now $155.10 +20.32% ▲ +1.66% +1.34% vs SPY
  10. May 7, 202627w ago 8-K Mixed 6/10 Entry $131.59 to $130.04 Now $155.10 +17.86% ▼ −1.18% −2.69% vs SPY
Showing 10 of 11

US Market Status

Market Closed · Opens Wed (12h 24m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 6, 2026